Lawrence B V, Lipton A, Harvey H A, Santen R J, Wells S A, Cox C E, White D S, Smart E K
Cancer. 1980 Feb 15;45(4):786-91. doi: 10.1002/1097-0142(19800215)45:4<786::aid-cncr2820450429>3.0.co;2-x.
Aminoglutethimide (AG) is an effective chemical ablative form of therapy for metastatic breast cancer in postmenopausal women. Estrogen receptor (ER) status in breast cancer is useful in predicting the response to the hormonal treatments. Of 134 postmenopausal metastatic breast cancer patients treated with AG, ER analysis was done in 63 patients, 52 of whom are now evaluable. ER biopsy was performed prior to Ag therapy in 61 patients, but the results were not known to the investigators. ER value greater than or equal to 10 fmol/mg cytosol protein was considered ER positive (ER+), 4-9.9 fmol/mg borderline, and less than 4 fmol/mg ER negative (ER-). In 38 ER+ patients, objective response rate was 50% (three complete response, 16 partial response) and eight stabilization. Median duration of objective response was 15 months. Forty-three percent of the patients with borderline estrogen receptor level responded objectively (three partial response) with the median duration of response eleven months. Fourteen percent of ER- patients responded objectively (one complete response). Hence the estrogen receptor level predicts response in ER+ and ER borderline patients treated with AG.
氨鲁米特（AG）是绝经后女性转移性乳腺癌一种有效的化学消融治疗方式。乳腺癌中的雌激素受体（ER）状态有助于预测对激素治疗的反应。在134例接受AG治疗的绝经后转移性乳腺癌患者中，对63例患者进行了ER分析，其中52例目前可进行评估。61例患者在AG治疗前进行了ER活检，但研究人员不知道结果。ER值大于或等于10 fmol/mg胞浆蛋白被认为是ER阳性（ER+），4 - 9.9 fmol/mg为临界值，小于4 fmol/mg为ER阴性（ER-）。在38例ER+患者中，客观缓解率为50%（3例完全缓解，16例部分缓解），8例病情稳定。客观缓解的中位持续时间为15个月。雌激素受体水平处于临界值的患者中有43%获得客观缓解（3例部分缓解），缓解的中位持续时间为11个月。14%的ER-患者获得客观缓解（1例完全缓解）。因此，雌激素受体水平可预测接受AG治疗的ER+和ER临界值患者的反应。
